{
    "ticker": "MRUS",
    "name": "Merus N.V.",
    "description": "Merus N.V. is a clinical-stage immuno-oncology company that is dedicated to advancing the treatment of cancer through its innovative approach to bispecific antibody technology. Founded in 2003 and headquartered in Utrecht, the Netherlands, Merus focuses on developing differentiated therapeutic antibodies that can simultaneously engage multiple tumor-associated targets. This dual-targeting capability is designed to enhance efficacy and improve patient outcomes in cancer treatment. Merus\u2019 lead product candidate, MCLA-128, is designed to target both HER2 and HER3, addressing the challenges of resistant tumors in patients with HER2-positive cancers. The company is committed to delivering novel therapies that can provide significant clinical benefits to patients suffering from various forms of cancer. With a robust pipeline of candidates in various stages of development, including collaborations with major pharmaceutical partners, Merus aims to leverage its proprietary technology platform to bring innovative solutions to market. As the landscape of cancer treatment evolves, Merus is at the forefront of research and development in bispecific antibodies, constantly striving to improve the quality of life for cancer patients worldwide.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Utrecht, Netherlands",
    "founded": "2003",
    "website": "https://www.merus.nl",
    "ceo": "Dr. Timo Van den Bogaard",
    "social_media": {
        "twitter": "https://twitter.com/MerusNVA",
        "linkedin": "https://www.linkedin.com/company/merus-nv/"
    },
    "investor_relations": "https://www.merus.nl/investors",
    "key_executives": [
        {
            "name": "Dr. Timo Van den Bogaard",
            "position": "CEO"
        },
        {
            "name": "Dr. Rainer F. G. Schmid",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutic Antibodies",
            "products": [
                "MCLA-128",
                "MCLA-117"
            ]
        }
    ],
    "seo": {
        "meta_title": "Merus N.V. | Innovative Bispecific Antibody Therapies",
        "meta_description": "Explore Merus N.V., a pioneering company in the field of bispecific antibodies for cancer treatment. Learn about our innovative therapies and commitment to improving patient outcomes.",
        "keywords": [
            "Merus",
            "Bispecific Antibodies",
            "Cancer Treatment",
            "Immuno-oncology",
            "MCLA-128",
            "MCLA-117"
        ]
    },
    "faq": [
        {
            "question": "What is Merus known for?",
            "answer": "Merus is known for its innovative bispecific antibody technology aimed at treating cancer."
        },
        {
            "question": "Who is the CEO of Merus?",
            "answer": "Dr. Timo Van den Bogaard is the CEO of Merus N.V."
        },
        {
            "question": "Where is Merus headquartered?",
            "answer": "Merus is headquartered in Utrecht, Netherlands."
        },
        {
            "question": "What are Merus' main products?",
            "answer": "Merus' main products include MCLA-128 and MCLA-117, both therapeutic antibodies."
        },
        {
            "question": "When was Merus founded?",
            "answer": "Merus was founded in 2003."
        }
    ],
    "competitors": [
        "AMGN",
        "REGN",
        "ABBV",
        "BMY"
    ],
    "related_stocks": [
        "AAPL",
        "MSFT",
        "GOOGL",
        "FB"
    ]
}